Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.74 |
| ▸ | FAP | Q12884 | 6/20 | 0.74 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.59 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.58 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1082946 | 0.99 | DPP4 (0.73) | DPP4FAPDPP7DPP8DPP9 | |
| Bromide SCHEMBL5203588 | 0.99 | DPP4 (0.73) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL20693851 | 0.89 | DPP4 (0.71) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL20693833 | 0.89 | DPP4 (0.71) | DPP4FAPDPP7DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL6070181 | 0.88 | DPP4 (0.70) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL5550719 | 0.85 | DPP4 (1.00) | DPP4FAPDPP7 | |
| SCHEMBL5202315 | 0.84 | DPP4 (0.76) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL6754510 | 0.84 | DPP4 (0.76) | DPP4FAPDPP7DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL5207093 | 0.83 | DPP4 (0.74) | DPP4FAPDPP7DPP8DPP9 | |
| SCHEMBL3164958 | 0.82 | DPP4 (0.73) | DPP4FAPDPP7DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1862457-A2 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SmithKline Beecham Corporation (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1406873-B1 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070112059-A1 | CYANOPYRROLIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. | 2007-05-17 | — | — | US | disclosed |
| US-20070112205-A1 | CYANOPYRROLIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. | 2007-05-17 | — | — | US | disclosed |
| EP-1746086-A1 | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-01-24 | — | — | EP | disclosed |
| US-20040072892-A1 | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1333025-A1 | CYANOPYRROLIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2003-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072892-A1 | Cyanopyrrolidine derivatives | CCR9, OPRD1, CBR1 | DPP4 2412/4885FAP 3334/4885DPP7 3078/4885 |
| US-20070112059-A1 | CYANOPYRROLIDINE DERIVATIVES | DPP4, DPP9, DPP3 | DPP4 1/4885FAP 40/4885DPP7 4/4885 |
| US-20070112205-A1 | CYANOPYRROLIDINE DERIVATIVES | CBR3, CBR1, TERT | DPP4 3721/4885FAP 2348/4885DPP7 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.